{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-099731","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2026-08-21T21:00:20+00:00","discovered_at":"2026-08-21T21:02:08.545799+00:00","generated_at":"2026-08-21T21:02:34.399093+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elutia completes SimpliDerm sale to Cellution for $11M; adds $7.7M net cash","bullets":["Closed Aug 17, 2026 sale of Women's Health hADM assets to Cellution Biologics.","Received $7.7M net cash ($8M at close less inventory adjustments); up to $3M contingent milestones over 18 months.","Transaction treated as discontinued operations; estimated pre-tax gain of $4.9M.","Pro forma H1 2026 continuing ops net loss $16.2M ($0.37/share) vs $15.5M reported.","NXT-41x (antibiotic-eluting biomatrix) FDA clearance expected H1 2027; funding secured through launch year 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-099731","json":"https://secwatch.observer/filing/0001104659-26-099731.json","markdown":"https://secwatch.observer/filing/0001104659-26-099731.md","text":"https://secwatch.observer/filing/0001104659-26-099731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/0001104659-26-099731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/elut-20260817x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-21T21:02:34.399093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}